Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244439 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice
A Phase 3 study of Lice Infestations, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 3
- Development phase
- 360
- Enrollment target
- 6
- Study locations
NCT00244439 is a Phase 3 study of Lice Infestations that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 360 participants. The trial reports 6 study locations across 4 states.
The verdict
NCT00244439, a Phase 3 study of Lice Infestations, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 360 participants
- Enrollment target
- 6
- Study locations
Study Summary
Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE (malathion 0.5%) lotion. In a previous phase II study, a novel, easy-to-use malathion 0.5% formulation was found to be a safe treatment for head lice. The current study will compare the efficacy and safety of this novel formulation of malathion with OVIDE and with an over-the-counter permethrin product.
Conditions Studied
Interventions
- DRUG MALG
- DRUG Ovide (malathion) lotion 0.05%
- DRUG Permethrin 1%
Study Locations (6)
Florida
- Investigator Site - Miami
- Investigator Site - St. Petersburg
- Investigator Site - West Palm Beach
Arizona
- Investigator Site - Scottsdale
New York
- Investigator Site - New York
Ohio
- Investigator Site - Miamiville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244439
The ClinicalTrials.gov registry entry for NCT00244439 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lice Infestations appearing as the primary indexed condition, and to 3 interventions - of which MALG is the first listed.
NCT00244439 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Florida, Arizona, New York.
Frequently Asked Questions
What is clinical trial NCT00244439 about?
NCT00244439 is a clinical study titled "Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice". Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE (malathion 0.5%) lotion. In a previous phase II study, a novel, easy-to-use malathion 0.5% formulation was found to be a safe treatment for head lice. The current study will ...
What is the current status of trial NCT00244439?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 360 participants. The study started on 2005-12. Estimated completion is 2006-12.
What conditions does trial NCT00244439 study?
This clinical trial studies the following conditions: Lice Infestations.
What interventions are being tested in trial NCT00244439?
The interventions under investigation include: MALG (DRUG), Ovide (malathion) lotion 0.05% (DRUG), Permethrin 1% (DRUG).
Who is sponsoring clinical trial NCT00244439?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00244439 being conducted?
This trial has 6 study locations across Arizona, Florida, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.